TALi Digital

TALi Digital Limited (ASX:TD1) is a digital health company headquartered in Australia that provides diagnostic and therapeutic solutions for cognitive function and behavior. The company was incorporated in 2004 and was formerly known as Novita Healthcare Limited, changing its name to TALi Digital Limited in December 2019. The technology is rooted in over 25 years of research in developmental psychology and cognitive neuroscience, initially developed at Monash University and commercialized through a spinout company, Tali Health, starting around 2014 before being acquired by TALi Digital.

The company's core business revolves around its patented digital platform designed to address attention difficulties in early childhood, a critical period for neuroplasticity. TALi targets children aged 3-8, an earlier intervention window than many other programs. The products are delivered as game-based applications on mobile or tablet devices, making them engaging for young users. The primary product suite includes TALi DETECT, a digital screening tool that assesses key areas of attention, and TALi TRAIN, a five-week cognitive training program designed to strengthen attention skills. These tools are intended for use by parents, healthcare professionals, and educators to support both neurodiverse and neurotypical children.

TALi Digital's business model incorporates both business-to-consumer (B2C) and business-to-business (B2B) streams. Revenue is generated through one-off payments for its programs, per-use fees, and licensing agreements. The company is pursuing a globally scalable model, establishing strategic partnerships to enter key international markets. A significant milestone was the 2021 strategic licensing agreement with Akili Interactive, a leader in digital therapeutics, to commercialize TALi's pediatric cognition products in the United States. This agreement includes potential milestone payments of up to AU$51 million plus royalties on future sales, with Akili leading the commercialization and regulatory clearance process in the U.S. Additionally, TALi has a partnership with The Times Group of India to target the consumer market in India, expanding its international reach.

The company's products are classified as medical devices, having secured FDA clearance in the U.S., a CE Mark in Europe, and inclusion on the Australian Register of Therapeutic Goods (ARTG). TALi is also focused on further product development for conditions such as ADHD and Autism Spectrum Disorder (ASD). The business strategy relies on layering recurring revenues from these diversified partnerships and markets to build long-term growth.

Keywords: digital therapeutics, cognitive training, pediatric attention, digital health, medical technology, neurodevelopment, cognitive assessment, early intervention, attention deficit, ADHD, gamified therapy, health-tech, Monash University, Akili Interactive, cognitive function, software as a medical device, edtech, behavioral health, neuroplasticity, cognitive care, brain health, digital diagnostics